Senzo

Executive Summary

Senzo Health is a UK-based diagnostics company founded in 2018, pioneering an Amplified Lateral Flow (ALF) test platform that aims to deliver PCR-level accuracy in a rapid, point-of-care format. The technology provides results within 10 minutes at a fraction of the cost of lab-based tests, targeting prevalent infectious diseases such as COVID-19, HIV, and Tuberculosis. By combining the speed and simplicity of lateral flow assays with signal amplification, Senzo's platform has the potential to decentralize testing and improve access in resource-limited settings. The company's progress to date suggests a strong pivot toward clinical validation and regulatory pathways. With the global diagnostics market shifting toward rapid, accurate, and affordable solutions, Senzo's ALF platform is well-positioned to capture significant market share. However, as a private company with limited public data, the risk remains around clinical performance and scalability. Future milestones, including clinical trial results and regulatory approvals, are critical for commercialization. Senzo's technology could address major gaps in infectious disease diagnostics, but execution and real-world validation will determine its ultimate impact.

Upcoming Catalysts (preview)

• Q4 2026Clinical Validation Results for Infectious Disease Panel60% success
• 2027CE Marking or Equivalent Regulatory Clearance40% success
• 2026Partnership with Global Health Organization for Distribution50% success